Farrell Simon - 18 Feb 2025 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role
Chief Commercial Officer
Signature
/s/ Christopher Galletta, attorney-in-fact
Issuer symbol
TRVI
Transactions as of
18 Feb 2025
Transactions value $
$0
Form type
4
Filing time
20 Feb 2025, 16:00:10 UTC
Previous filing
16 Feb 2024
Next filing
12 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRVI Stock Option (right to buy) Award $0 +226K $0.00 226K 18 Feb 2025 Common Stock 226K $4.22 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on February 18, 2025. The 225,500 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 18, 2026 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 18, 2029.